Effects of PINTA 745 in End Stage Renal Disease (ESRD) Patients Who Require Hemodialysis and Have Protein Energy Wasting

NCT01958970 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

51

Enrollment

INDUSTRY

Sponsor class

Conditions

End Stage Renal Disease
Kidney Disease
Protein Energy Wasting

Interventions

DRUG: PINTA 745
DRUG: Placebo

Sponsor

Pinta Biotherapeutics